FDA approves RHA Redensity Eye for infraorbital volume loss

On August 20, 2026, the FDA approved RHA Redensity Eye for correcting moderate to severe infraorbital volume deficiencies in adults aged 22 and older, providing clinicians with a highly predictable, on-label hyaluronic acid option for the delicate undereye area. Part of the Teoxane RHA Collection distributed by Revance, the filler uses Preserved Network Technology to create a soft, stretchable gel optimized to integrate smoothly into the expressive periorbital anatomy. Notably, the product is formulated with mepivacaine for local anesthesia.

The approval is supported by a 52-week U.S. pivotal clinical study where 93 percent of patients demonstrated visible aesthetic improvement at three months. These corrective effects lasted up to 12 months without requiring touch-ups. From a clinical safety perspective, the trial data is exceptionally clean for this technically challenging zone, reporting no late-onset or serious treatment-related adverse events, no granulomas, no delayed inflammatory responses, and no vascular occlusions.

For practice owners, this clearance directly addresses a common patient demand while mitigating the typical risks of off-label tear trough treatments, such as superficial product migration or unnatural swelling. Having a dedicated, FDA-approved product with a forgiving rheological profile helps secure predictable patient outcomes. If you already carry the Teoxane line, incorporating this into your treatment menus requires minimal operational friction and offers a strong talking point for patients seeking durable, natural-looking undereye rejuvenation.

Source: Dermatology Times, https://www.dermatologytimes.com/view/fda-clears-rha-redensity-eye-for-undereye-hollows-offering-soft-stretchable-ha-filler-with-12-month-results-and-strong-safety-data-in-a-52-week-study